acitretin has been researched along with Congenital Erythropoietic Porphyria in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azuero-Dajud, R; Bragazzi Cunha, J; Elenbaas, JS; Ferguson, AC; Griffin, MS; Kuo, N; Lentz, SI; Maitra, D; Omary, MB; Shavit, JA | 1 |
1 other study(ies) available for acitretin and Congenital Erythropoietic Porphyria
| Article | Year |
|---|---|
Acitretin mitigates uroporphyrin-induced bone defects in congenital erythropoietic porphyria models.
Topics: Acitretin; Animals; Bone and Bones; Bone Development; Cell Line; Disease Models, Animal; Porphyria, Erythropoietic; Uroporphyrins; Zebrafish | 2021 |